Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Update

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the recipient of a significant drop in short interest in June. As of June 30th, there was short interest totaling 116,653 shares, a drop of 46.4% from the June 15th total of 217,647 shares. Based on an average daily trading volume, of 52,848 shares, the days-to-cover ratio is presently 2.2 days. Approximately 0.7% of the company’s shares are short sold.

Analysts Set New Price Targets

Several brokerages have issued reports on MRKR. Weiss Ratings restated a “sell (d-)” rating on shares of Marker Therapeutics in a report on Wednesday, June 24th. HC Wainwright reiterated a “buy” rating on shares of Marker Therapeutics in a report on Wednesday, May 20th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $10.00.

Marker Therapeutics Stock Down 5.0%

Shares of Marker Therapeutics stock traded down $0.07 during mid-day trading on Thursday, hitting $1.34. The stock had a trading volume of 69,079 shares, compared to its average volume of 183,196. The firm has a 50-day moving average of $1.43 and a two-hundred day moving average of $1.52. The firm has a market cap of $22.34 million, a P/E ratio of -2.20 and a beta of 1.45. Marker Therapeutics has a 12-month low of $0.81 and a 12-month high of $4.07.

Marker Therapeutics (NASDAQ:MRKR) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 73.29%. The firm had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.78 million. Sell-side analysts expect that Marker Therapeutics will post -1.17 earnings per share for the current year.

Institutional Investors Weigh In On Marker Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRKR. Virtu Financial LLC purchased a new position in shares of Marker Therapeutics during the 3rd quarter worth $25,000. Two Sigma Investments LP acquired a new stake in shares of Marker Therapeutics during the 3rd quarter worth about $33,000. Jane Street Group LLC purchased a new stake in Marker Therapeutics in the 2nd quarter valued at about $33,000. Boyer Financial Services Inc. purchased a new stake in Marker Therapeutics in the 4th quarter valued at about $57,000. Finally, XTX Topco Ltd lifted its position in Marker Therapeutics by 166.6% in the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after buying an additional 36,269 shares during the last quarter. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.